Budesonid

Budesonid
Klinički podaci
Prodajno ime	Bidien, Budeson, Budicort, Cortivent
Drugs.com	Monografija
Način primene	Respiratorno (inhalacija), oralno
Farmakokinetičkipodaci
Poluvreme eliminacije	2,0 - 3,6 h
Izlučivanje	Renalno
Identifikatori
CAS broj	51333-22-3
ATC kod	A07EA06(WHO),R03BA02
PubChem	CID40000
DrugBank	DB01222
ChemSpider	36566
ChEBI	CHEBI:3207
ChEMBL	CHEMBL1370
Hemijski podaci
Formula	C25H34O6
Molarna masa	430,54 g·mol−1
	SMILES [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C; ;
	InChI InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1; Key:VOVIALXJUBGFJZ-KWVAZRHASA-N;

Budesonid(BUD), u prodaji pod imenomPulmicortizmeđu ostalih, je lekkortikosteroidnogtipa.^[1]On je dostupan u inhalacionom obliku, kao pilula,nazalni sprej,i u rektalnoj formi.^[1]^[2]Inhalaciona forma se koristi u dugotrajnom tretmanuastmeihronične opstruktivne bolesti pluća(COPD).^[1]^[3]^[4]Nazalni sprej se koristi zaalergijski rinitisinazalne polipe.^[2]^[5]Pilule sa odloženim oslobađanjem i rektalne forme se mogu koristiti za tretmanupalnih bolesti crevauključujućiKronovu bolest,ulcerozni kolitisimikroskopski kolitis.^[6]^[7]

Osobine

Budesonid jeorgansko jedinjenje,koje sadrži 25atoma ugljenikai imamolekulsku masuod 430,534Da.^[8]^[9]

Osobina	Vrednost
Broj akceptora vodonika	6
Broj donora vodonika	2
Broj rotacionih veza	4
Particioni koeficijent^[10](ALogP)	2,2
Rastvorljivost^[11](logS,log(mol/L))	-4,2
Polarna površina^[12](PSA,Å²)	93,1

Reference

^^а ^б ^в„Budesonide”.The American Society of Health-System Pharmacists.Приступљено2. 12. 2015.
^^а ^б„Budesonide eent”.The American Society of Health-System Pharmacists.Приступљено2. 12. 2015.
^De Coster, DA; Jones, M (2014). „Tailoring of corticosteroids in COPD management.”.Current respiratory care reports.3:121—132.PMID 25089228.doi:10.1007/s13665-014-0084-2.
^Christophi, GP; Rengarajan, A; Ciorba, MA (2016).„Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach.”.Clinical and experimental gastroenterology.9:125—30.PMC4876845 .PMID 27274301.doi:10.2147/CEG.S80237.
^Rudmik, L; Schlosser, RJ; Smith, TL; Soler, ZM (2012).„Impact of topical nasal steroid therapy on symptoms of nasal polyposis: a meta-analysis.”.The Laryngoscope.122(7): 1431—7.PMID 22410935.doi:10.1002/lary.23259.
^Silverman J, Otley A (2011). „Budesonide in the treatment of inflammatory bowel disease.”.Expert Rev Clin Immunol.7(4): 419—28.PMID 21790284.doi:10.1586/eci.11.34.
^Pardi DS, Tremaine WJ, Carrasco-Labra A (2016). „American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis”.Gastroenterology.150(1): 247—274.e11.PMID 26584602.doi:10.1053/j.gastro.2015.11.006.
^Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39(Database issue): D1035—41.PMC3013709 .PMID 21059682.doi:10.1093/nar/gkq1126.
^David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic acids research.36(Database issue): D901—6.PMC2238889 .PMID 18048412.doi:10.1093/nar/gkm958.
^Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”.J. Phys. Chem. A.102:3762—3772.doi:10.1021/jp980230o.
^Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Chem Inf. Comput. Sci.41:1488—1493.PMID 11749573.doi:10.1021/ci000392t.
^Ertl P.; Rohde B.; Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”.J. Med. Chem.43:3714—3717.PMID 11020286.doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001).Goodman & Gilman's The Pharmacological Basis of Therapeutics(10. изд.). New York: McGraw-Hill.ISBN 0071354697.doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007).Foye's Principles of Medicinal Chemistry(6. изд.). Baltimore: Lippincott Willams & Wilkins.ISBN 0781768799.

Spoljašnje veze

Budesonide

Molimo Vas, obratite pažnju navažno upozorenje
u vezi sa temama izoblasti medicine (zdravlja).

[AHFS2015-1] а ^б ^в„Budesonide”.The American Society of Health-System Pharmacists.Приступљено2. 12. 2015.

[AHFS2015ENT-2] а ^б„Budesonide eent”.The American Society of Health-System Pharmacists.Приступљено2. 12. 2015.

[3] De Coster, DA; Jones, M (2014). „Tailoring of corticosteroids in COPD management.”.Current respiratory care reports.3:121—132.PMID 25089228.doi:10.1007/s13665-014-0084-2.

[4] Christophi, GP; Rengarajan, A; Ciorba, MA (2016).„Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach.”.Clinical and experimental gastroenterology.9:125—30.PMC4876845 .PMID 27274301.doi:10.2147/CEG.S80237.

[5] Rudmik, L; Schlosser, RJ; Smith, TL; Soler, ZM (2012).„Impact of topical nasal steroid therapy on symptoms of nasal polyposis: a meta-analysis.”.The Laryngoscope.122(7): 1431—7.PMID 22410935.doi:10.1002/lary.23259.

[Sil2011-6] Silverman J, Otley A (2011). „Budesonide in the treatment of inflammatory bowel disease.”.Expert Rev Clin Immunol.7(4): 419—28.PMID 21790284.doi:10.1586/eci.11.34.

[7] Pardi DS, Tremaine WJ, Carrasco-Labra A (2016). „American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis”.Gastroenterology.150(1): 247—274.e11.PMID 26584602.doi:10.1053/j.gastro.2015.11.006.

[8] Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39(Database issue): D1035—41.PMC3013709 .PMID 21059682.doi:10.1093/nar/gkq1126.

[9] David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic acids research.36(Database issue): D901—6.PMC2238889 .PMID 18048412.doi:10.1093/nar/gkm958.

[10] Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”.J. Phys. Chem. A.102:3762—3772.doi:10.1021/jp980230o.

[11] Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Chem Inf. Comput. Sci.41:1488—1493.PMID 11749573.doi:10.1021/ci000392t.

[12] Ertl P.; Rohde B.; Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”.J. Med. Chem.43:3714—3717.PMID 11020286.doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]